2-(2-chlorophenyl)-5,7-dihydroxy-8-nitrochromen-4-one | 920006-41-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 2-(2-chlorophenyl)-5,7-dihydroxy-8-nitrochromen-4-one
• CAS: 920006-41-3
• 化学式: C₁₅H₈ClNO₆
• 分子量: 333.685
• InChiKey: MFUAYZDJJDSJNG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(2-chlorophenyl)-5,7-dihydroxy-8-nitrochromen-4-one 在 氢氧化钾 、 tin chloride hydrate 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 水 为溶剂， 反应 5.92h， 生成 4-chloro-N-[2-(2-chlorophenyl)-5,7-dihydroxy-4-oxo-4H-chromen-8-yl]benzamide
  参考文献：
  名称：

  Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues

  摘要：

  The design and synthesis of a small library of 8-amidoflavone, 8-sulfonamidoflavone, 8-amido-7-hydroxyflavone, and heterocyclic analogues of flavopiridol is reported. The potential activity of these compounds as kinase inhibitors was evaluated by cytotoxicity studies in MCF-7 and ID-8 cancer cell lines and inhibition of CDK2-Cyclin A enzyme activity in vitro. The anti-proliferative and CDK2-Cyclin A inhibitory activity of these analogues was significantly lower than the activity of flavopiridol. Molecular docking simulations were carried out and these studies suggested a different binding orientation inside the CDK2 binding pocket for these analogues compared to flavopiridol. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.10.063
• 作为产物：
  描述：

  2',4',6'-tris(2-chlorobenzoyloxy)acetophenone 在 吡啶 、 氢氧化钾 、 硝酸 、 溶剂黄146 作用下， 反应 5.5h， 生成 2-(2-chlorophenyl)-5,7-dihydroxy-8-nitrochromen-4-one
  参考文献：
  名称：

  Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues

  摘要：

  The design and synthesis of a small library of 8-amidoflavone, 8-sulfonamidoflavone, 8-amido-7-hydroxyflavone, and heterocyclic analogues of flavopiridol is reported. The potential activity of these compounds as kinase inhibitors was evaluated by cytotoxicity studies in MCF-7 and ID-8 cancer cell lines and inhibition of CDK2-Cyclin A enzyme activity in vitro. The anti-proliferative and CDK2-Cyclin A inhibitory activity of these analogues was significantly lower than the activity of flavopiridol. Molecular docking simulations were carried out and these studies suggested a different binding orientation inside the CDK2 binding pocket for these analogues compared to flavopiridol. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.10.063

文献信息

• COMPOSITIONS AND METHODS FOR MONITORING, DIAGNOSIS, PROGNOSIS, DETECTION, AND TREATMENT OF CANCER
  申请人：Shrivastava Shivani

  公开号：US20220168422A1

  公开（公告）日：2022-06-02

  The present invention relates to the use of compositions for treating or preventing a cancer condition in a subject. The use of composition comprises methods of treating or preventing cancer with agents that inhibit Nanog expression and/or activity. The pharmaceutical composition will further comprise agents that inhibit Nanog expression or activity in a subject.
• Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues
  作者：Yu Mi Ahn、Lakshminarayana Vogeti、Chun-Jing Liu、Hari K.R. Santhapuram、Jonathan M. White、Veena Vasandani、Lester A. Mitscher、Gerald H. Lushington、Paul R. Hanson、Douglas R. Powell、Richard H. Himes、Katherine F. Roby、Qizhuang Ye、Gunda I. Georg

  DOI：10.1016/j.bmc.2006.10.063

  日期：2007.1

  The design and synthesis of a small library of 8-amidoflavone, 8-sulfonamidoflavone, 8-amido-7-hydroxyflavone, and heterocyclic analogues of flavopiridol is reported. The potential activity of these compounds as kinase inhibitors was evaluated by cytotoxicity studies in MCF-7 and ID-8 cancer cell lines and inhibition of CDK2-Cyclin A enzyme activity in vitro. The anti-proliferative and CDK2-Cyclin A inhibitory activity of these analogues was significantly lower than the activity of flavopiridol. Molecular docking simulations were carried out and these studies suggested a different binding orientation inside the CDK2 binding pocket for these analogues compared to flavopiridol. (c) 2006 Elsevier Ltd. All rights reserved.